Although the cathecholamine systems have long been the focus of drug therapy in anxiety
and depression, the development of novel drugs specifically aimed at new targets within
these traditional neurotransmitter systems and at targets outside of these systems is now
propelling the field of drug development in anxiety. A greater understanding of regional
brain networks implicated in stress, anxiety, and anxious behaviors has provided localized
targets for anxiolytics. Within the serotonin and norepinephrine systems, increased …